|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Curis, Inc. (CRIS) to Release First Quarter 2012 Financial Results and Hold Conference Call on May 8, 2012
5/1/2012 10:20:22 AM
LEXINGTON, Mass., May 1, 2012 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today announced that the Company will release its first quarter financial results on Tuesday, May 8, 2012, before the market opens. The Company will also hold a conference call on the same day at 9:00 A.M. Eastern time to discuss: (i) Erivedge™ (vismodegib), a hedgehog pathway inhibitor under collaboration with Genentech that is the first and only FDA-approved medicine for people with advanced forms of basal cell carcinoma, (ii) CUDC-101, CUDC-907, Debio 0932 and other network-targeted cancer programs, (iii) its financial results as of and for the three-month period ended March 31, 2012, and (iv) additional corporate activities. Daniel Passeri, President and Chief Executive Officer of Curis, will host the call.
|
|
|
|
|
|
|
|
|
|
|